Impact of Synthetic and Biological Immunomodulatory Therapy on the Duration of 17DD Yellow Fever Vaccine-Induced Immunity in Rheumatoid Arthritis

Clarissa de Castro Ferreira,Ana Carolina Campi-Azevedo,Vanessa Peruhype-Magalhāes,Jordana Grazziela Coelho-dos-Reis,Lis Ribeiro do Valle Antonelli,Karen Torres,Larissa Chaves Freire,Ismael Artur da Costa-Rocha,Ana Cristina Vanderley Oliveira,Maria de Lourdes de Sousa Maia,Sheila Maria Barbosa de Lima,Carla Magda Domingues,Andréa Teixeira-Carvalho,Olindo Assis Martins-Filho,Lícia Maria Henrique da Mota, on behalf of the Collaborative Group for Studies of Yellow Fever Vaccine

Arthritis research & therapy（2019）

引用 10|浏览26

暂无评分

摘要

The 17DD-yellow fever (YF) vaccine induces a long-lasting protective immunity, resulting from humoral and cellular immunological memory. The treatment of rheumatoid arthritis (RA) patients with disease-modifying anti-rheumatic drugs (DMARD) may affect pre-existing 17DD-vaccine protective immunity and increase the risk of acquiring YF infection. Our goal was to determine whether DMARD would affect the duration of YF-specific protective immunity in RA patients.

查看译文

关键词

Immunomodulatory therapy,Yellow fever vaccine,Neutralizing antibodies,Cellular immunity,Rheumatoid arthritis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要